Liraglutide Evidence Guide
Liraglutide is FDA-approved for type 2 diabetes (Victoza) and obesity (Saxenda), with Phase 3 RCT data (SCALE trial) showing 8-9% body weight reduction - meaningful but less than semaglutide or tirzepatide. It is well-characterized with a long safety record. For weight management research where once-daily dosing is acceptable, liraglutide is a solid, established reference compound.
Our Take
Liraglutide is FDA-approved for type 2 diabetes (Victoza) and obesity (Saxenda), with Phase 3 RCT data (SCALE trial) showing 8-9% body weight reduction - meaningful but less than semaglutide or tirzepatide. It is well-characterized with a long safety record. For weight management research where once-daily dosing is acceptable, liraglutide is a solid, established reference compound.
- Best for
- Obesity, type 2 diabetes, weight management research, GLP-1 reference compound
- Evidence grade
- Level A
- Confidence
- High
- Starting point
- 0.6mg subcutaneous daily, titrating to 3mg over 5 weeks (Saxenda dosing)
Benefits and Evidence
- Weight Loss: Level A, includes human evidence - SCALE trials demonstrated ~8% weight loss with 3.0mg daily dose. Less weight loss than semaglutide but well-established efficacy and safety profile.
- Blood Sugar Control: Level A, includes human evidence - Extensive clinical data supporting HbA1c reduction. LEAD trial program demonstrated superiority over several diabetes medications.
- Cardiovascular Protection: Level A, includes human evidence - LEADER trial showed 13% reduction in major adverse cardiovascular events. First GLP-1 to demonstrate CV benefits in a dedicated outcomes trial.
Side Effects and Warnings
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Headache
- Injection site reactions
- Boxed warning: thyroid C-cell tumors in rodents
- Pancreatitis risk
Research Dosage References
- <strong>Subcutaneous (diabetes)</strong> - 0.6-1.8 mg - Once daily - Start 0.6mg for one week, increase to 1.2mg, max 1.8mg (Victoza).
- <strong>Subcutaneous (weight)</strong> - 0.6-3.0 mg - Once daily - Gradual escalation over 5 weeks to target 3.0mg dose (Saxenda).
Mechanism of Action
Liraglutide shares the GLP-1 mechanism: 1. GLP-1 receptor activation: Binds to and activates GLP-1 receptors throughout the body. 2. Appetite suppression: Central appetite regulation through hypothalamic GLP-1 receptors. 3. Insulin secretion: Glucose-dependent insulin stimulation from pancreatic beta cells. 4. Glucagon reduction: Suppresses inappropriate glucagon secretion. 5. Gastric slowing: Delays gastric emptying, contributing to satiety and glycemic control.
Legal Status
FDA-approved for type 2 diabetes (Victoza, 2010) and chronic weight management (Saxenda, 2014). Prescription required. Widely available globally.
Primary Sources
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med, 2016.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE). N Engl J Med, 2015.